About SHIVOM coin and Token sale detalis

mdmohsingazi2001 (6)in #blockchain • 7 years ago

THIS EXECUTIVE SUMMARY MAY NOT BE DISTRIBUTED IN OR TRANSMITTED TO THE UNITED
STATES OR TO U.S. PERSONS. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO
SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY OMX TOKENS IN THE UNITED STATES
OR TO U.S. PERSONS. THE OMX TOKENS HAVE NOT BEEN REGISTERED WITH THE U.S.
SECURITIES AND EXCHANGE COMMISSION OR UNDER ANY STATE SECURITIES LAWS AND MAY
NOT BE ACQUIRED, OFFERED, SOLD OR TRADED IN THE UNITED STATES OR BY U.S. PERSONS
IN THE ABSENCE OF REGISTRATION UNDER APPLICABLE U.S. FEDERAL AND STATE LAWS OR
IN RELIANCE UPON AN APPLICABLE EXEMPTION.

This company idea
The world of healthcare is changing. Two revolutionary technologies, genomics,
and blockchain, are poised to significantly improve health and well-being across
the globe. Genomic medicine can enhance the understanding and treatment of as
many as 7,000 rare diseases, alongside cancers, complex and long-term disease
such as cardiovascular and neurodegenerative conditions, and infections.
Likewise, blockchain technology will transform both the future of healthcare
and the world economy: it is poised to herald the biggest transformation in
innovation since the advent of the internet and web 2.0. Shivom is the next
evolutionary step in this development, bringing these technologies together to
create a revolutionary medical genomics ecosystem that will open up healthcare
opportunities for all.
Shivom offers the first ever integrated solution for patients and genome data
donors where everybody will be able to have their genome sequenced and
securely stored. This ecosystem will provide an open web-marketplace for
other providers such as pharmaceuticals, research organizations, governments,
patient-support groups and insurance companies to add their apps and services,
alongside genomic data analytics and personalized medicine.
The cost of DNA sequencing has fallen significantly. It is anticipated that by the
end of the decade it will be possible to generate a person’s entire genome for less
than $100. Looking ahead further, we will see dramatically lower costs for genomic
analysis services. This will make personalized healthcare insights accessible to
almost all individuals around the globe. As recently as January 2017, the worldwide
leading sequencing provider Illumina unveiled a new sequencer, the NovaSeq, that
the company reports will eventually provide a whole genome for less than $100.
This presents a new dawn for access to personalized and precision healthcare on a
global scale.
Over the last 10 years “Next-Generation” (NGS) DNA Sequencing technologies and data-analytics have
led to a dramatic reduction in costs. Shown here using a logarithmic scale.

Genomics and artificial intelligence present a unique opportunity to
revolutionize R&D programs, especially screening for drug targets and
corresponding drug candidates. The significant cost associated with drug
development is linked to the ability to access high-quality and validated
datasets from patients.
We are currently engaging with partners in leading pharmaceutical/biotech
companies and clinical research organizations (CROs) to allow access to
our services, as well as offer the opportunity to sponsor genomic testing
on a mass level.
The data will not be owned by any company, and the Shivom platform will
facilitate pharmaceutical companies’ use of the data by providing attractive
rewards and a market access model that directly engages with data owners.
The model will allow access to study and control patients through an app
marketplace for phenotypic screening and more.

We aim to build a global network of genetic counselors who can also form a
telemedicine ecosystem (in case people in rural areas have no direct access
to healthcare). Eventually, most people will undergo genetic testing and
counseling, not only those with clearly elevated genetic risks.

Our counselors and laboratories will also work as an information hub. As
genomic data become more common in the clinic, it is imperative that clinical
scientists and physicians use automated and standardized tools which employ
up-to-date methods and curated publications.

Shivom will distribute 3 billion OmiX tokens
Token Sale
990M OmiX tokens will be sold during the ICO process.
Community
90M OmiX Tokens will be distributed to the community to grow and nurture the
Shivom ecosystem, for bounty programs to leverage network effects, and for
community initiatives to reward developers, entrepreneurs, and strategists.
Founders
420M OmiX will be allocated for founders to support the development of the
Shivom ecosystem and their continued long-term alignment with the project.
Advisors
300M OmiX will be allocated for early backers and a global network of advisors.
Incentivizing Growth Pool
600M OmiX will be secured in a smart contract, allocated to the database, and
introduced into circulation as rewards for data generation.
Company Reserve
600M OmiX will be kept by the Foundation as a reserve fund for future data
contribution, running the Foundation and associated non-profit R&D efforts. The
Foundation maintains all authority to utilize a few or the majority of the reserve
tokens for future external investors.
TOKEN SALE: USE OF PROCEEDS

20% Platform Development
Database building, UI, APIs, and metadata curating. A large part of this budget will
be used to make the platform secure and scalable. From there we will implement
new features and create the open marketplace.
11% Operations & Business Development
Day-to-day operations, team building (developers, geneticists, marketers and
product managers). Forming the Foundation.
10% Non-Profit R&D Platform
Drug discovery platform combining elements of Big Data analytics, artificial
intelligence, genomics, proteomics, lipidomics, and metabolomics.
21% Marketing & Forming Partnerships
Ongoing community-building events public communications via traditional
marketing channels and persona-based approaches. This also includes educational
materials, roadshows, collaboration with other genomics-initiatives, organizing
events and conferences, and KOL management.
5% Legal
Regulatory compliance for all markets Shivom operates in.
2% Initial PoC
First sequencing project in hospitals in rural India.
6% Data Storage
Forecasted to sustain the platform during the first few years.
25% Laboratories
Setting up a global network of laboratories and counseling services.